Holen Sie sich die Stockscreener-App
0.00
100.00%
-13.85
Schlusskurs vom Vortag:
$13.85
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$18.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.14M
KGV:
0.00
EPS:
-13.985
Netto-Cashflow:
$-22.40M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$16.52
52-Wochen-Spanne:
$0.00
$36.76
Faeth Therapeutics Inc Stock (SNSE) Company Profile
Firmenname
Faeth Therapeutics Inc
Sektor
Branche
Telefon
(240) 243-8000
Adresse
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNSE
Faeth Therapeutics Inc
|
0.00 | 18.59M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-06-29 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2021-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-01 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Faeth Therapeutics Inc Aktie (SNSE) Neueste Nachrichten
Faeth Therapeutics Launches New At-the-Market Equity Program - The Globe and Mail
Faeth Therapeutics, Inc. Enters At-The-Market Sales Agreement with TD Securities to Sell Common Stock on Nasdaq - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Faeth Therapeutics Launches $150 Million ATM Stock Offering With TD Securities - TradingView
Faeth Therapeutics (NASDAQ: SNSE) launches $150M at-the-market stock program - Stock Titan
Faeth Therapeutics (NASDAQ: FTH) launches $150M ATM sales agreement with TD Cowen - Stock Titan
FTH Price Today: Faeth Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
EBITDA per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Return on assets % of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Price to cash flow ratio of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Faeth Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US81728A2078 - marketscreener.com
Non-controlling/minority interest of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Faeth Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | 4070 | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | FTH | US81728A2078 - marketscreener.com
FTH: Static price chart | Faeth Therapeutics, Inc. | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Performance & Quotes, FTH Stock Price on Nasdaq Exchange - marketscreener.com
Faeth Therapeutics, Inc. Stock (FTH)Quote Nasdaq - marketscreener.com
FTH (Faeth Therapeutics) Cyclically Adjusted PS Ratio : (As of Jun. 17, 2026) - GuruFocus
Faeth Therapeutics Inc (FTH) Stock Earnings Transcripts - GuruFocus
Faeth Therapeutics, Inc. (FTH) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Faeth Therapeutics, Inc. (FTH) Stock Live Price, Chart & News - CoinCodex
Total liabilities of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Operating income of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total revenue of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Director at Sensei Biotherapeutics (NASDAQ: SNSE) awarded 25,000 stock options - Stock Titan
Net current asset value per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Enterprise value to EBITDA ratio of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Sensei Biotherapeutics (SNSE) CEO converts Series B preferred into 761,428 common shares - Stock Titan
Director Ramasastry lists merger-based options in Sensei Biotherapeutics (SNSE) - Stock Titan
Net debt of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Director at Sensei Biotherapeutics (NASDAQ: SNSE) gains shares, options - Stock Titan
Sensei Biotherapeutics (SNSE) director reports Series B preferred stake from merger - Stock Titan
Diluted earnings per share (diluted EPS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total debt of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
EBIT of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Free cash flow of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Free float of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Net income of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Dilution adjustment of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc. Balance Sheet – NASDAQ:FTH - TradingView
Operating expenses (excl. COGS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc. Cash Flow – NASDAQ:FTH - TradingView
Basic earnings per share (basic EPS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Net margin % of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total operating expenses of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Cash per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Discontinued operations of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
After tax other income/expense of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Finanzdaten der Faeth Therapeutics Inc-Aktie (SNSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):